Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Condition(s):Cerebrotendinous XanthomatosesLast Updated:August 12, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Cerebrotendinous XanthomatosesLast Updated:August 12, 2022Completed
Condition(s):Xanthomatosis, CerebrotendinousLast Updated:April 1, 2021Unknown status
Condition(s):Cerebrotendinous Xanthomatosis (CTX)Last Updated:June 7, 2012Unknown status
Condition(s):Cerebrotendinous Xanthomatosis (CTX)Last Updated:November 9, 2018Unknown status
Condition(s):CTX – Cerebrotendinous XanthomatosisLast Updated:June 15, 2022Terminated
Condition(s):Cerebrotendinous XanthomatosisLast Updated:June 24, 2005Unknown status
Condition(s):Cerebrotendinous XanthomatosisLast Updated:March 29, 2021Unknown status
Condition(s):CTXLast Updated:March 2, 2023Recruiting
Condition(s):Cerebrotendinous XanthomatosisLast Updated:October 14, 2013Withdrawn
Condition(s):Alagille Syndrome; Atorvastatin; XanthomaLast Updated:February 8, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.